Comparison of Loading Doses of Ziv-Aflibercept and Aflibercept in Neovascular Age-Related Macular Degeneration. Issue 2 (March 2020)

• Record Type: Journal Article
• Authors: Ayachit, Apoorva; Singh, Sumit Randhir; Subramanyam, Anand; Tiwari, Sarvesh; Heranjal, Abhishek; Chattannavar, Goura; Pandey, Priti; Salti, Haitham; Mansour, Mohamad A; Mansour, Ahmad; Chhablani, Jay
• Is Part Of: Asia-Pacific journal of ophthalmology. Volume 9:Issue 2(2020)
• Publication Date: 2020-03
• Subjects: aflibercept -- neovascular age related macular degeneration (n-AMD) -- ziv-aflibercept; Ophthalmology -- Periodicals; Eye -- Diseases -- Periodicals; Periodicals; 617.7005
• DOI: 10.1097/APO.0000000000000277
• Languages: English
• ISSNs: 0129-1653

Abstract

Abstract : Purpose: The aim of this study was to compare outcomes of 3 loading doses of ziv-aflibercept and aflibercept in treatment-naïve neovascular age-related macular degeneration (nAMD). Design: Retrospective, nonrandomized, comparative study. Methods: This was a retrospective chart review which included cases with treatment-naïve nAMD. The patients were divided into 2 groups (group 1, ziv-aflibercept; group 2, aflibercept). Groups 1 and 2 received 1.25 mg/0.05 mL of intravitreal ziv-aflibercept and 2 mg/0.05 mL aflibercept, respectively every month for 3 months. Best-corrected visual acuity (BCVA) in Snellen and logarithm of minimum angle of resolution (logMAR), central subfoveal thickness (CSFT), subretinal hyperreflective material height, neurosensory detachment height, and pigment epithelial detachment height were recorded at baseline and 3 monthly follow-up. Results: Twenty-three eyes of 23 patients were included (males 14, females 9). Twelve and 11 eyes were included in group 1 and group 2, respectively. Group 1 showed statistically significant improvement in BCVA ( P < 0.001) and CSFT ( P =0.007) through 3 months compared with baseline. There was significant change in BCVA from baseline at 1st month ( P = 0.007), 2nd month ( P = 0.002) and 3rd month ( P = 0.008). In group 2, there was no significant improvement in BCVA, CSFT, subretinal hyperreflective material height, neurosensory detachment, and pigment epithelial detachment height from baseline through 3 months. Conclusions: After 3 loading doses, ziv-aflibercept showed efficacy in terms of improved BCVA and reduction of CSFT from baseline whereas aflibercept did not show such improvement. Considering the cost- effectiveness and the proven safety of ziv-aflibercept, it is a viable option for the crucial, initial 3 doses in the treatment of nAMD.